Alpha Cancer Technologies secures angel financing

Photo of author

By Ted Liu

Alpha Cancer Technologies Inc. (ACT) has closed a private round of financing, raising $[mepr-active rule=”374″ ifallowed=”hide”]##Subscribe today to see our research on this and all other subscriber ONLY items##[/mepr-active][mepr-active rule=”374″]800,000 from 9 BC, Alberta, Saskatchewan, Ontario and US investors. [/mepr-active]

Alpha Cancer Technologies Inc. (ACT) is a private clinical stage biotechnology company with products under development in auto-immune and oncology disease indications. The company’s drug products use proprietary recombinant human alpha fetoprotein (AFP) with unique immuno-oncology properties.

Alpha Cancer Technologies has raised over $15 million in equity funding and about $3 million in government funding. Celgene, one of the world’s largest biotechnology companies owns a 12% equity stake in ACT.

Alpha Cancer Technologies board of directors consists of Richard Potts, Chairman, Dr. Igor Sherman, President and CEO, Jeffrey Puritt, President and CEO of TELUS International, Borys Chabursky, founder and Chairman of Shift Health, and Christopher W. Morgan, Partner at Skadden, Arps, Slate, Meagher & Flom LLP.

photo credit: Alpha Cancer Technologies